ISPOR RWE Registry Empowers RWD Studies

January 5, 2022

The Real-World Evidence (RWE) Registry by ISPOR, ISPE, Duke Margolis Center for Health Policy, and the National Pharmaceutical Council allows researchers to preregister their real-world data study protocols. Preregistration offers several benefits, such as increasing confidence in study results, widening the impact of studies on the field, and fast-tracking peer review in ISPOR’s Value in Health journal. Moreover, the drive towards preregistration helps bolster the field as a whole.

According to a publication in Value & Outcomes Spotlight by Richard J Willke and Shirley V. Wang, “If real-world evidence (RWE) is to be seriously considered for healthcare decision making as a useful complement to randomized controlled trial data, it must become “adult” in the sense of satisfying the same requirements for registration, sharing of study protocols, and results.”